Development of method to distinguish lentinan binding ability of human peripheral blood monocytes

Biotherapy

Volumn 20, Issue 1, 2006, Pages 79-83

  Suga, Yasuyo ^a   Takai, Kenji ^b   Kondoh, Hiroshi ^c   Sano, Akiko ^c   Sugita, Toshiaki ^b   Hazama, Shoichi ^c   Yoshino, Shigefumi ^c   Suga, Tetsuya ^a   Oka, Masaaki ^c   Murata, Masahiro ^a  

^a AJINOMOTO CO INC   (Japan)

^b SRL INC   (Japan)

^c YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

1,3 Glucan (lentinan); Anti tumor effects; Dextran; Lentinan binding; Monocyte

Indexed keywords

ANTINEOPLASTIC AGENT; BETA 1,3 GLUCAN; LENTINAN;

ARTICLE; CANCER SURVIVAL; DRUG BINDING; LENTINUS EDODES; MONOCYTE; NONHUMAN; QUALITY OF LIFE;

EID: 33644527581     PISSN: 09142223     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Hamuro, J., Hadding, U. and Bitter-Suermann, D.: Solid phase activation of alternative pathway of complement bete-1,3-glucans and its possible role for tumour regressing activity. Immunology 34: 695-705, 1978.
2. Brown, G. D. and Gordon, S.: A new receptor for β-glucan. Nature 413: 36-37, 2001.
3. Oka, M., Hazama, S., Suzuki, T., et al.: In vitro and in vivo analysis of human leukocyte binding by the antitumor polysaccharide, lentinan. Int. J. Immunopharmac. 18(3): 211-216, 1996.
4. th Annual Meeting, 1991.
5. Biotherapy 19(2): 197-203, 2005.
6. Kishida, E., Sone, Y., Misaki, A., et al.: Preparation and immunochemical characterization of antibody to branched β-(1-3)-D-glucan of Volvariella volvacea, and its use in studies of antitumor actions. Agric. Biol. Chem. 53(7): 1849-1859, 1989.